����������

The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested for 60 days on market concentration and contracting practices among group purchasing organizations and drug wholesalers to understand their potential impact on pricing and generic drug shortages.

“For years Americans have faced acute shortages of critical drugs, from chemotherapy to antibiotics, endangering patients,” FTC Chair Lina Khan. “Our inquiry requests information on the factors driving these shortages and scrutinizes the practices of opaque drug middlemen. We look forward to public input as we assess how enforcers and policymakers can best address chronic drug shortages and promote a resilient drug supply chain.”